Shifting the focus in lymphoma treatment
Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas
Mathias J Rummel
Smouldering myeloma: detection, risk stratification and defining a new standard of care
ADCT-402 - a drug to watch
Is venetoclax appropriate for relapsed CLL patients?